(E)-1-chloro-3-phenylbutan-2-one | 854466-26-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-1-chloro-3-phenylbutan-2-one
• 英文别名: 1-chloro-3-phenylbutan-2-one；1-chloro-3-phenyl-butan-2-one；1-Chlor-3-phenyl-butan-2-on；1-Chlor-3-phenyl-2-butanon
• CAS: 854466-26-5
• 化学式: C₁₀H₁₁ClO
• 分子量: 182.65
• InChiKey: CDITUJWGRFYLBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-1-chloro-3-phenylbutan-2-one 在 水 、 barium carbonate 作用下， 生成 1-hydroxy-3-phenylbutan-2-one
  参考文献：
  名称：

  Panizzi; Pepe, Annali di Chimica, 1953, vol. 43, p. 29,33

  摘要：

  DOI：
• 作为产物：
  描述：

  α-甲基苯腈 在 重氮甲烷 、 氢氧化钾 、 五氯化磷 作用下， 生成 (E)-1-chloro-3-phenylbutan-2-one
  参考文献：
  名称：

  Panizzi; Pepe, Annali di Chimica, 1953, vol. 43, p. 29,33

  摘要：

  DOI：

文献信息

• Methods and Compositions for Selectin Inhibition
  申请人：Kaila Neelu

  公开号：US20080255192A1

  公开（公告）日：2008-10-16

  The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

  本教学涉及到式I的新化合物： 其中组成变量如本文所定义。本教学的化合物可以作为被称为选择素的哺乳动物粘附蛋白的拮抗剂。提供了治疗或预防选择素介导的疾病的方法，包括以治疗有效剂量给予这些化合物。
• Copper(I)-Promoted Synthesis of Chloromethyl Ketones from Trichloromethyl Carbinols
  作者：Ram N. Ram、T. P. Manoj

  DOI：10.1021/jo8007644

  日期：2008.7.1

  Reaction of several trichloromethyl carbinols with 2 equiv of CuCl/bpy in refluxing DCE for 3 h afforded chloromethyl ketones in excellent yield by 1,2-H shift in the copper-chlorocarbenoid intermediate.

  几种三氯甲基甲醇与2当量的CuCl / bpy在回流DCE中反应3小时，得到的氯甲基酮的收率很高，通过铜-氯类化合物中间体的1,2-H转移。
• Crystal structure of glutamate racemase (MurI)
  申请人：Anderson Marie

  公开号：US20050037478A1

  公开（公告）日：2005-02-17

  The present invention discloses crystals of MurI from Gram negative, Gram positive, and atypical bacterium; computer-assisted method for screening, identifying, and designing inhibitors of MurI; inhibitors of MurI; and uses thereof.

  本发明公开了来自革兰氏阴性、革兰氏阳性和非典型细菌的 MurI 晶体；用于筛选、鉴定和设计 MurI 抑制剂的计算机辅助方法；MurI 抑制剂及其用途。
• Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury
  作者：Adrian Huang、Alessandro Moretto、Kristin Janz、Michael Lowe、Patricia W. Bedard、Steve Tam、Li Di、Valerie Clerin、Natalia Sushkova、Boris Tchernychev、Desiree H. H. Tsao、James C. Keith、Gray D. Shaw、Robert G. Schaub、Qin Wang、Neelu Kaila

  DOI：10.1021/jm9013696

  日期：2010.8.26

  Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure activity-studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.
• EP0502892A4
  申请人：——

  公开号：EP0502892A4

  公开（公告）日：1992-11-19